H.R 1 - Monitored development of the One Big Beautiful Bill Not-for-Profit Hospital Tax-exemption - Provided education and information on hospital tax exemption and what is required to justify and maintain tax-exempt status.
Acute Hospital Care at Home - Recommended Congress make certain flexibilities related to the Acute Hospital Care at Home Program permanent or, pass an extension before flexibilities expire. CMS FY 2026 Hospital Inpatient Prospective Payment System (IPPS) for Acute Care Hospitals and Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals proposed rule - Responded to various issues and proposals provided in the Proposed Rule and offered our responses to the agencys various requests for information. CMS Medicare Drug Price Negotiation Program: Draft Guidance - Encouraged CMS to consider minimizing provider burden, including avoiding disruptions to current purchasing and reimbursement practices ; urged CMS to avoid final guidance that enables a retrospective payment of the 340B discount H.R 1 - Monitored development of the One Big Beautiful Bill Issues related to hospital and provider payment - Supported increasing hospital reimbursement to ensure continued access to care for vulnerable populations, highlighted the criticality of Medicaid to sustaining vital healthcare services. Hosted congressional briefing to educate on hospital finances. Medicaid Disproportionate Share Hospital (DSH) Program - Urged Congress to avert the cuts to Medicaid DSH payments set to take place, encouraged passage of legislation to preserve DSH payments on a longer-term basis Opportunities to Update the Patient Safety Indicators - Provide feedback to the Agency for Healthcare Research and Quality (AHRQ) on future Patient Safety Indicator (PSI) measurement and related analyses. Physician Payment - Urged Congress to consider long-term legislative solutions to refine the current Medicare physician payment system Prior Authorization - Provided feedback to improve prior authorization (PA) processes for various plans and payers, including MA organizations and Medicaid managed care plans. Rural Emergency Hospital (REH) Designation - Urged corrective action to allow REHs to bill both the Medicare and Medicaid programs. Advocated for increased eligibility among REHs to allow for future Medicaid DSH payments to certain hospital facilities. Site-Neutral Payment Policies - Opposed adoption of site-neutral payment policies for drug administration and increased fines related to price transparency requirements for hospitals. Urged Congress to redirect its focus from site-neutral payment policies to reducing administrative burdens and increasing, rather than reducing, payments for care delivery in rural areas.
340B Drug Pricing Program - Continued to urge action to ensure covered entities have access to 340B discounted prices through contract pharmacies. Highlighted critical importance of the 340B program for hospitals. Children's Hospital Graduate Medical Education (CHGME) - Continued to urge Congress to increase funding for and reauthorize the CHGME program Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for a surges in demand Endorsed passage of the Drug Competition Enhancement Act (S.1040) Endorsed passage of the Affordable Prescriptions for Patients Act (S.1041) Endorsed passage of the Save Healthcare Workers Act (H.R.3178/S.1600) Endorsed passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (H.R.4191/S.1784) Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. H.R 1 - Monitored development of the One Big Beautiful Bill Mental and Behavioral Health - Highlighted the need for legislation to address significant challenges to mental and behavioral health treatment, including increased demand for services, limited access to treatment, and clinician shortages. Non-medical drivers of health outcomes - Encouraged Congress and agencies to ensure tools like the Vizient Vulnerability Index are being utilized to understand data about disparities in health. Highlighted opportunities for the increased use of secondary health data in a clinical setting. Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications. Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients - Offered recommendations on the importance of considering incentives to support domestic manufacturing and financial support to providers Rural healthcare - Advocated for policies and initiatives that address the challenges of rural communities by promoting access to care and strengthening healthcare infrastructure Telehealth - Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current expiration date. Telemedicine prescribing - Encouraged DEA to finalize a telemedicine prescribing framework that is more similar to the flexibilities that have been in place since the COVID-19 PHE United States Core Data for Interoperability Draft Version 6 - Offer recommendations to constructively improve Draft USCDI v6, including additional requesting clarification on several data elements Workforce - Advocated for strengthening the health workforce through policies that support education, training, recruitment, and retention efforts
Implementation of Additional Duties on Products of the Peoples Republic of China, EO 14256 - Monitored implementation of tariffs on pharmaceuticals, medical supplies and other healthcare products; supporting exclusions for key healthcare products. Implementation of Additional Duties on Products of Canada, EO 14193 - Monitored the implementation of tariffs on pharmaceuticals, medical supplies and other healthcare products; supporting exclusions for key healthcare products. Implementation of Additional Duties on Products of Mexico, EO 14194 - Monitored the implementation of tariffs on pharmaceuticals, medical supplies and other healthcare products; supporting exclusions for key healthcare products. Monitored development of the Medical Supply Chain Resiliency Act (S.998)